Dunhill Financial’s Skye Bioscience SKYE Stock Holding History

Dunhill Financial’s Portfolio SKYE Stock Details SKYE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6	Closed	-$1.96K	–	1143
2025 Q1	$1.96K	Buy	+6	New	+$131	﹤0.01%	736
2024 Q3	–	Sell	-6	Closed	-$401	–	981
2024 Q2	$401	Buy	+6	New	+$570	﹤0.01%	760

Other funds holding SKYE

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Dunhill Financial's SKYE Position: Q2 2025 in Review

Dunhill Financial sold out of Skye Bioscience (SKYE) in Q2 2025, closing a stake of 6 shares — an estimated $1.96K sold.

Dunhill Financial first reported a position in SKYE in Q2 2024 and held it in 2 quarters. The position peaked at $1.96K in Q1 2025. 55 funds tracked by Wall St. Rank hold SKYE as of Q2 2025.

Dunhill Financial reported no remaining Skye Bioscience position as of Q2 2025 after selling out during the quarter.
Dunhill Financial sold 6 Skye Bioscience shares in Q2 2025, an estimated $1.96K.
Dunhill Financial first reported a position in Skye Bioscience in Q2 2024 and held it in 2 quarters.
Dunhill Financial's Skye Bioscience position peaked at $1.96K in Q1 2025.
55 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2025.

Based on Dunhill Financial's 13F filing for Q2 2025, filed 5 Aug 2025.